Jääskeläinen, Minna M.
Tiainen, Satu http://orcid.org/0000-0002-5673-8851
Siiskonen, Hanna
Ahtiainen, Maarit
Kuopio, Teijo
Rönkä, Aino
Kettunen, Tiia
Hämäläinen, Kirsi
Rilla, Kirsi
Harvima, Ilkka
Mannermaa, Arto
Auvinen, Päivi
Funding for this research was provided by:
Suomen Kulttuurirahasto (65202120)
Kuopion Yliopistollinen Sairaala
University of Eastern Finland (UEF) including Kuopio University Hospital
Article History
Received: 30 March 2023
Accepted: 19 June 2023
First Online: 10 July 2023
Declarations
:
: Satu Tiainen has received consulting fees or honoraria for speaking at symposia and participating in advisory boards and consulting, and financial support for attending conferences from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Pfizer, Roche, Sanofi Genzyme and Takeda. Minna Jääskeläinen has received financial support from Amgen and Roche for attending conferences and owns shares in Faron Pharmaceuticals. Aino Rönkä has received consulting fees or honoraria for speaking at symposia and participating in advisory boards and financial support for attending conferences from Amgen, Bristol-Myers Squibb, Merck, Novartis, Pfizer and Roche, and Tiia Kettunen from AbbVie, Amgen, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Pfizer, Pierre Fabre, Roche and Sobi. Päivi Auvinen reports funding for attending ESMO Breast Cancer Congress from Roche. None of the financial support of any of the authors was related to the work described in this study. All other authors declare that they have no conflict of interest.
: This study was conducted in accordance with the ethical standards of The Ethics Committee of the University of Eastern Finland (February 24, 2009, 19//2009), and the 1964 Declaration of Helsinki and its later amendments.
: Informed consent was not required since this is a retrospective study conducted on already existing material.